AZD1775 induces toxicity through double-stranded DNA breaks independently of chemotherapeutic agents in p53-mutated colorectal cancer cells

Peter John WebsterSchool of Medicine, University of Leeds, Leeds, UKView further author information

Anna Tiffany LittlejohnsSchool of Medicine, University of Leeds, Leeds, UK

http://orcid.org/0000-0002-7566-0121 View further author information

Hannah Jane GauntSchool of Medicine, University of Leeds, Leeds, UKView further author information

K. Raj PrasadDepartment of Hepatobiliary and Transplant Surgery, St. James's University Hospital, Leeds, UKView further author information

David John BeechSchool of Medicine, University of Leeds, Leeds, UKView further author information

Dermot Anthony BurkeSchool of Medicine, University of Leeds, Leeds, UK;Department of Colorectal Surgery, St. James's University Hospital, Leeds, UKCorrespondence[email protected]
View further author information

Pages 2176-2182 | Received 29 Nov 2016, Accepted 24 Feb 2017, Published online: 09 Nov 2017

Cite this article
https://doi.org/10.1080/15384101.2017.1301329
CrossMark

Full Article
Figures & data
References
Supplemental
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians 2015; 65:87–108.
PubMed Web of Science ®Google Scholar
Watanabe N, Broome M, Hunter T. Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle. EMBO J 1995; 14:1878–91; PMID:7743995
PubMed Web of Science ®Google Scholar
Wang Y, Li J, Booher R, Kraker A, Lawrence T, Leopold W, Sun Y. Radiosensitization of p53 Mutant Cells by PD0166285, a Novel G2 Checkpoint Abrogator. Cancer Res 2001; 61:8211–7; PMID:11719452
PubMed Web of Science ®Google Scholar
Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, Sakai N, Imagaki K, Ohtani J, Sakai T, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 2009; 8:2992–3000; PMID:19887545; http://dx.doi.org/10.1158/1535-7163.MCT-09-0463
PubMed Web of Science ®Google Scholar
Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, Imagaki K, Ohtani J, Sakai T, Yoshizumi T et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 2010; 9:514–22; http://dx.doi.org/10.4161/cbt.9.7.11115
PubMed Web of Science ®Google Scholar
Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, Shumway SD, Mizuarai S, Hirai H, Maitra A et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 2011; 17:2799–806; PMID:21389100; http://dx.doi.org/10.1158/1078-0432.CCR-10-2580
PubMed Web of Science ®Google Scholar
Kreahling JM, Gemmer JY, Reed D, Letson D, Bui M, Altiok S. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Mol Cancer Ther 2012; 11:174–82; PMID:22084170; http://dx.doi.org/10.1158/1535-7163.MCT-11-0529
PubMed Web of Science ®Google Scholar
Van Linden AA, Baturin D, Ford JB, Fosmire SP, Gardner L, Korch C, Reigan P, Porter CC. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality. Mol Cancer Ther 2013; 12:2675–84; PMID:24121103; http://dx.doi.org/10.1158/1535-7163.MCT-13-0424
PubMed Web of Science ®Google Scholar
Guertin AD, Li J, Liu Y, Hurd MS, Schuller AG, Long B, Hirsch HA, Feldman I, Benita Y, Toniatti C et al. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy. Mol Cancer Ther 2013; 12:1442–52; PMID:23699655; http://dx.doi.org/10.1158/1535-7163.MCT-13-0025
PubMed Web of Science ®Google Scholar
Mueller S, Hashizume R, Yang X, Kolkowitz I, Olow AK, Phillips J, Smirnov I, Tom MW, Prados MD, James CD et al. Targeting Wee1 for the treatment of pediatric high-grade gliomas. Neuro-oncology 2014; 16:352–60; PMID:24305702; http://dx.doi.org/10.1093/neuonc/not220
PubMed Web of Science ®Google Scholar
Cuneo KC, Morgan MA, Davis MA, Parcels LA, Parcels J, Karnak D, Ryan C, Liu N, Maybaum J, Lawrence TS. Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress. Int J Radiat Oncol Biol Phys 2016; 95:782–90; PMID:26975930; http://dx.doi.org/10.1016/j.ijrobp.2016.01.028
PubMed Web of Science ®Google Scholar
Beck H, Nähse-Kumpf V, Larsen MS, O'Hanlon KA, Patzke S, Holmberg C, Mejlvang J, Groth A, Nielsen O, Syljuåsen RG et al. Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption. Mol Cell Biol 2012; 32:4226–36; PMID:22907750; http://dx.doi.org/10.1128/MCB.00412-12
PubMed Web of Science ®Google Scholar
Pfister SX, Markkanen E, Jiang Y, Sarkar S, Woodcock M, Orlando G, Mavrommati I, Pai CC, Zalmas LP, Drobnitzky N et al. Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation. Cancer Cell 2015; 28:557–68; PMID:26602815; http://dx.doi.org/10.1016/j.ccell.2015.09.015
PubMed Web of Science ®Google Scholar
Do K, Wilsker D, Ji J, Zlott J, Freshwater T, Kinders RJ, Collins J, Chen AP, Doroshow JH, Kummar S. Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors. J Clin Oncol 2015; 33(30):3409–15; PMID:25964244; http://dx.doi.org/10.1200/JCO.2014.60.4009
PubMed Web of Science ®Google Scholar
Matheson CJ, Backos DS, Reigan P. Targeting WEE1 Kinase in Cancer. Trends Pharmacol Sci 2016; 37(10):872–81; PMID:27427153; http://dx.doi.org/10.1016/j.tips.2016.06.006
PubMed Web of Science ®Google Scholar
Kreahling JM, Foroutan P, Reed D, Martinez G, Razabdouski T, Bui MM, Raghavan M, Letson D, Gillies RJ, Altiok S. Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas. PloS one 2013; 8:e57523; PMID:23520471; http://dx.doi.org/10.1371/journal.pone.0057523
PubMed Web of Science ®Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

AZD1775 induces toxicity through double-stranded DNA breaks independently of chemotherapeutic agents in p53-mutated colorectal cancer cells

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

AZD1775 induces toxicity through double-stranded DNA breaks independently of chemotherapeutic agents in p53-mutated colorectal cancer cells

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date